South Korea Antibody Production Market Size, Share, and COVID-19 Impact Analysis, By Product (Instruments, Consumables, and Software), By Type (Monoclonal Antibody and Polyclonal Antibody), By End-use (Pharmaceutical and Biotechnology Companies and CROs and CDMOs), and South Korea Antibody Production Market, Industry Trend, Forecasts to 2035

South Korea Antibody Production Market Insights Forecasts to 2035

• The South Korea Antibody Production Market Size Was Estimated at USD 294.3 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 15.22% from 2025 to 2035
• The South Korea Antibody Production Market Size is Expected to Reach USD 1,398.9 Million by 2035

According to a research report published by Spherical Insights & Consulting, The South Korea Antibody Production Market Size is anticipated to reach USD 1398.9 Million by 2035, growing at a CAGR of 15.22% from 2025 to 2035. Rapid market expansion has resulted from the rising incidence of chronic illnesses like diabetes, cancer, and cardiovascular conditions as well as the rising need for therapeutic antibodies.

Market Overview

The antibody production market involves the manufacturing of antibodies used for diagnostics, therapeutics, and research. Antibodies, such as monoclonal and polyclonal types, play a crucial role in disease detection, treatment, and biopharmaceutical development. Benefits include high specificity, improved disease targeting, and advancements in personalized medicine. The growing prevalence of chronic diseases, increasing biopharmaceutical R&D, and technological innovations present significant growth opportunities. Governments worldwide, including South Korea, support the market through funding, regulatory frameworks, and initiatives promoting biotech innovation and healthcare advancements. These efforts accelerate antibody production capabilities, enhance quality standards, and foster collaborations between academia and industry, driving market expansion and enabling better healthcare solutions.

Report Coverage

This research report categorizes the market for South Korea antibody production market based on various segments and regions forecasts revenue growth, and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the South Korea antibody production market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment South Korea antibody production market.

Driving Factors

The rising demand for targeted therapies, especially in cancer and autoimmune diseases, due to antibodies’ high specificity and effectiveness. Increasing investments in biopharmaceutical R&D and advancements in production technologies also fuel growth. Growing prevalence of chronic illnesses, government support for biotech innovation, and expanding applications in diagnostics and personalized medicine further boost market demand.

Restraining Factors

The high manufacturing costs and complex production processes, which limit scalability and accessibility. Regulatory challenges and stringent quality control requirements can delay product approvals and increase expenses. Additionally, intellectual property issues and competition from alternative therapies like small molecules or gene editing pose challenges. Limited skilled workforce and supply chain disruptions also hinder growth.

Market Segmentation

The South Korea antibody production market share is classified into product, type, and end-use.

• The instruments segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea antibody production market is segmented by product into instruments, consumables, and software. Among these, the instruments segment held a significant share in 2024 and is expected to grow at a substantial CAGR during the forecast period. The increasing demand for advanced bioprocessing equipment, automation, and high-throughput technologies. Continued investments in biotech R&D and growing biopharmaceutical production drive this trend. Instruments offer efficiency, precision, and scalability.

• The monoclonal antibody segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea antibody production market is segmented by type into monoclonal antibody and polyclonal antibody. Among these, the monoclonal antibody segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. The growing use in precision medicine, particularly for cancer and chronic diseases. These antibodies offer high specificity, reproducibility, and therapeutic effectiveness. Strong government support for biotech innovation and increased pharmaceutical R&D.

• The automotive segment dominated a share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea antibody production market is segmented by end-use into automotive, aerospace, construction, marine, and electrical. Among these, the automotive segment dominated a share in 2024 and is expected to grow at a significant CAGR during the forecast period. The increasing integration of advanced biosensors and smart materials in vehicle systems. The push for enhanced safety, emissions control, and fuel efficiency has driven demand for antibody-based technologies in diagnostics and monitoring applications. Additionally, strong automotive manufacturing infrastructure, coupled with rising investments in innovation and R&D, supports continued growth.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the South Korea antibody production market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the companies' current news and developments, including product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Celltrion Inc.
• Samsung Biologics Co., Ltd.
• GC Pharma (Green Cross Corporation)
• Medytox Inc.
• Genexine, Inc. 
• PharmAbcine Inc.
• Aptabio Therapeutics Inc.
• Daewoong Pharmaceutical
• Hanmi Pharmaceutical
• SK Biopharmaceuticals
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at South Korea, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the South Korea antibody production market based on the below-mentioned segments:

South Korea Antibody Production Market, By Product

• Instruments
• Consumables
• Software

South Korea Antibody Production Market, By Type

• Monoclonal Antibody
• Polyclonal Antibody

South Korea Antibody Production Market, By End-use

• Pharmaceutical
• Biotechnology Companies
• CROs and CDMOs